Hyperbaric Oxygen Therapy and SPECT Brain Imaging in Cerebral Decompression Illness

Overview

Chart review of patients who received hyperbaric oxygen therapy for cerebral decompression illness who also underwent SPECT brain blood flow imaging to see if SPECT brain imaging tracks and is consistent with the clinical condition of the patients.

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: N/A
    • Intervention Model: Single Group Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: December 2017

Detailed Description

SPECT brain imaging has been shown to be the most sensitive imaging modality for cerebral decompression illness. This study is a retrospective review of the PI's experience using SPECT brain imaging in the diagnosis and treatment of all phases of cerebral decompression illness over the past two decades. The purpose of the study is to see if the functional imaging is consistent with the clinical condition and cognitive testing. Chart review of symptoms, and physical exam findings will be compared before and after treatment to SPECT brain imaging radiological readings to assess concordance.

Interventions

  • Drug: Hyperbaric oxygen therapy
    • total body exposure to greater than atmospheric pressure oxygen

Arms, Groups and Cohorts

  • Experimental: Hyperbaric oxygen therapy
    • Hyperbaric oxygen therapy

Clinical Trial Outcome Measures

Primary Measures

  • SPECT brain imaging
    • Time Frame: Within one month after completion of hyperbaric oxygen therapy
    • Comparison of SPECT brain imaging chart copy of radiological reading before or early in the treatment history to SPECT brain imaging chart copy of radiological reading after treatment. Imaging will be scored as better, worse, or no change based on resolution of defects or improvement in pattern of injury.

Secondary Measures

  • Symptoms of cerebral decompression illness
    • Time Frame: Within one month after hyperbaric oxygen therapy
    • Chart reports of patients’ symptoms of cerebral decompression illness before hyperbaric oxygen therapy will be compared to symptoms after hyperbaric oxygen therapy and rated as better, worse, or no change.
  • Abnormal physical exam findings
    • Time Frame: Within one month after hyperbaric oxygen therapy
    • Chart reports of abnormal physical exam findings before hyperbaric oxygen therapy will be compared to chart reports of physical exam findings after hyperbaric oxygen therapy and rated as better, worse, or no change.

Participating in This Clinical Trial

Inclusion Criteria

  • All patients in the P.I.'s practice who underwent hyperbaric oxygen therapy for cerebral decompression illness in the previous two decades who also underwent SPECT brain blood flow imaging early in the course of treatment and following completion of hyperbaric oxygen therapy.

Exclusion Criteria

  • none

Gender Eligibility: All

Minimum Age: N/A

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Paul G. Harch, M.D.
  • Collaborator
    • Harch Hyperbaric Research Foundation
  • Provider of Information About this Clinical Study
    • Sponsor-Investigator: Paul G. Harch, M.D., Clinical Professor of Medicine – Louisiana State University Health Sciences Center in New Orleans
  • Overall Official(s)
    • Paul G Harch, M.D., Principal Investigator, LSU School of Medicine
  • Overall Contact(s)
    • Paul G Harch, M.D., 504-309-4948, paulharchmd@gmail.com

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.